Allergan PLC tried to focus on the positive Phase III data released for its acute migraine candidate ubrogepant during the firm's quarterly earnings call Feb. 6, but analysts and investors seem concerned about elevated liver enzyme cases seen in the study that Allergan maintains are not drug-related.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?